KKR Allocates Up to $200 Million to Expand Healthium MedTech in India
KKR has set aside $150-200 million to acquire additional assets to expand Healthium MedTech, a medical devices maker it acquired last year for about ₹7,000 crore. The investment aims to grow Healthium's product portfolio, enter new therapy areas, and capitalize on the rapidly growing Indian medtech market, projected to rise from $12 billion to $50 billion by 2028.
KKR, a global private equity firm, plans to invest $150-200 million to scale Healthium MedTech through acquisitions in India, focusing on expanding product offerings in cardiology, orthopaedics, and diagnostics. Healthium, bought by KKR in 2023 for about ₹7,000 crore (~$840 million), develops and sells surgical products globally, with revenues growing at 15% annually over the last five years. The investment is part of KKR’s broader strategy of consolidation through bolt-on acquisitions to leverage operational synergies in fragmented sectors like healthcare. The Indian medtech market is anticipated to grow significantly, supporting KKR’s commitment to scaling Healthium. Healthium’s recent financial performance shows revenue growth but a profit decline due to non-cash ESOP expenses and prior year gains. KKR has a strong healthcare presence across India and Asia-Pacific through investments in companies like JB Chemicals, Max Healthcare, and Gland Pharma. The firm is also focused on operational growth and future IPOs for its Indian healthcare portfolio. KKR's approach highlights a trend in private equity to deepen investment in high-growth, scalable healthcare platforms using capital allocation and consolidation strategies.
